Recombinant GDF15 prophylaxis attenuates cardiorenal toxicity and fibrosis induced by doxorubicin and angiotensin II
Recombinant GDF15 pretreatment can protect the heart and kidneys from Dox-induced cardiorenal toxicity and Ang II-exacerbated injury and encourage further investigation into GDF15 as a potential prophylaxis against cardiorenal toxicity associated with anthracycline chemotherapy and renin-angiotensin system activation.